The ED Drug That Failed a Heart-Failure Test

A drug can work in one pulmonary disease and fail in another

Tadalafil has a real place in pulmonary vascular medicine.

Under the Adcirca name, tadalafil is indicated for pulmonary arterial hypertension, or PAH, to improve exercise ability in WHO Group 1 patients. The approved PAH dose is 40 mg once daily. (pi.lilly.com)

That fact can create a tempting assumption:

If tadalafil helps some pulmonary-hypertension patients, maybe it should help other patients with high lung pressures too.

The PASSION trial tested that assumption in a different disease state: heart failure with preserved ejection fraction, or HFpEF, complicated by combined postcapillary and precapillary pulmonary hypertension.

That is the research issue behind Cialis Professional tadalafil HFpEF CpcPH PASSION trial.

The target was not ordinary ED physiology

HFpEF is a form of heart failure in which the heart’s pumping percentage may look preserved, but filling pressures are abnormal. Some patients develop pulmonary hypertension because pressure backs up from the left side of the heart into the lung circulation. In more advanced cases, the pulmonary vessels themselves may also remodel, producing combined postcapillary and precapillary pulmonary hypertension, often shortened to CpcPH.

This is not the same condition as classic Group 1 PAH.

In PAH, pulmonary arterial disease is the primary problem. In HFpEF-CpcPH, pulmonary pressure is tied to left-heart disease plus pulmonary vascular changes. That distinction matters because a vasodilator can help in one setting and fail, or even cause harm, in another.

What PASSION tested

PASSION was a randomized, double-blind, placebo-controlled, multicenter phase 3 trial in Germany. It evaluated tadalafil in patients with HFpEF and CpcPH. Eligible patients had left ventricular ejection fraction of at least 50%, elevated pulmonary pressures on right-heart catheterization, pulmonary capillary wedge pressure above 15 mmHg, and pulmonary vascular resistance above 3 Wood units. (American College of Cardiology)

Patients were assigned to tadalafil or placebo. Tadalafil was started at 20 mg once daily and increased to 40 mg once daily after 4 weeks if tolerated. The primary endpoint was event-free survival, defined as time to first heart-failure hospitalization or death from any cause. (American College of Cardiology)

The trial planned to recruit 372 patients, but it was stopped early because of study-drug production and supply problems. At termination, 125 patients had been randomized: 62 to tadalafil and 63 to placebo. (American College of Cardiology)

The result did not support tadalafil

The available data did not show a significant benefit on the composite endpoint of heart-failure hospitalization or death.

Primary endpoint events occurred in 17 patients assigned to tadalafil and 20 assigned to placebo. More concerningly, all-cause death was higher in the tadalafil group: 9 of 62 patients, compared with 2 of 63 in the placebo group. The hazard ratio for all-cause death was 5.10, with a 95% confidence interval of 1.10 to 23.69. (American College of Cardiology)

Because the trial ended early, the result must be interpreted carefully.

But the conclusion was still clinically important: PASSION did not support tadalafil use in HFpEF-CpcPH, and the mortality imbalance raised a potential safety concern. (American College of Cardiology)

Why this matters for Cialis Professional users

Cialis Professional-style products are usually framed around sexual performance: stronger effect, longer duration, more confidence, better timing.

The PASSION trial sits far outside that marketing frame.

It shows that tadalafil is not a simple “blood-flow enhancer.” It is a systemic PDE5 inhibitor whose effects depend heavily on the disease context. In erectile dysfunction, the target is penile vascular response. In approved PAH therapy, the target is pulmonary arterial disease. In HFpEF-CpcPH, the problem includes left-heart filling pressure, pulmonary vascular resistance, right-heart strain, fluid status, comorbidities, and fragile hemodynamics.

The same pathway does not mean the same outcome.

The practical takeaway

Cialis Professional should not be treated as a general cardiovascular improver.

Tadalafil can be medically useful in specific approved settings, but the PASSION trial shows the danger of extending a plausible mechanism into a different heart-lung disease without proof. In HFpEF with combined postcapillary and precapillary pulmonary hypertension, tadalafil did not show clear clinical benefit and raised possible safety concerns.

Mechanism can justify a trial.

It cannot replace the result.

Disclaimer

This article is for informational and educational purposes only. It is not medical advice, diagnosis, or treatment. Tadalafil or any erectile dysfunction medication should be used only under the guidance of a qualified healthcare professional.

References

1. Hoeper MM, et al. PASSION trial: tadalafil for combined postcapillary and precapillary pulmonary hypertension in HFpEF. (American College of Cardiology)

2. American College of Cardiology journal scan: PASSION design, early termination, no observed benefit, and mortality safety signal. (American College of Cardiology)

3. Adcirca prescribing information: tadalafil indication for WHO Group 1 pulmonary arterial hypertension to improve exercise ability. (pi.lilly.com)

4. ACC PHIRST trial summary: tadalafil 40 mg daily improved 6-minute walk distance in pulmonary arterial hypertension. (American College of Cardiology)